Goldman Sachs has initiated coverage of Sigma Healthcare shares (ASX:SIG) with a Buy rating and A$3.50 price target, becoming the latest major investment bank to back the Australian pharmacy giant following its transformative merger with Chemist Warehouse Group.
Sigma Healthcare shares closed at A$2.92 on the ASX today, holding steady despite the bullish call from Goldman Sachs. The investment bank’s A$3.50 price target implies upside of approximately 19.9% from current levels.
The stock has attracted considerable attention from institutional investors in recent months, with shares up substantially from pre-merger levels as markets digest the strategic combination that created Australia’s largest pharmacy franchise and wholesale operation.
Core Details
Goldman Sachs joins a growing chorus of Wall Street firms expressing confidence in Sigma Healthcare’s post-merger trajectory. The investment bank cited upside potential in the company’s margin estimates and attractive valuation as key drivers behind its Buy recommendation, though specific financial projections from Goldman were not disclosed.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The bullish sentiment follows Sigma’s strong maiden financial results since completing its merger with Chemist Warehouse Group in February 2025. On August 27, 2025, the company reported an 82% surge in revenue to A$6 billion and a 41.4% increase in underlying EBIT to A$834.5 million, demonstrating robust operational momentum in the combined entity.
BofA Securities has been among the most optimistic, reinstating coverage on December 19, 2025, with a Buy rating and A$3.90 price target—the highest among major brokers. The firm highlighted Sigma’s powerful brand portfolio spanning Chemist Warehouse, Amcal, and Discount Drug Store, projecting the pharmaceutical industry would deliver 8% annual growth driven by demographic tailwinds including an aging population and rising chronic illness prevalence.
UBS initiated coverage on November 19, 2025, with a Buy rating and A$3.40 target, emphasising Chemist Warehouse’s leadership position in the health and beauty market, which is expanding at 6% annually and outpacing broader retail growth. The firm expects Sigma to capitalise on sales strength through comparable store growth and network expansion, delivering meaningful operating leverage.
JPMorgan entered the fray on September 19, 2025, with an Overweight rating and A$3.30 target, describing Sigma’s profile as a “rare combination of double-digit growth at scale.” The firm identified potential synergies of A$100 million over four years to underpin long-term growth and praised Sigma’s global market reach and robust balance sheet.
Outlook and Analysis
Not all analysts share the bullish view. Macquarie retained its Underperform rating in August 2025 with a A$2.50 price target, acknowledging strong execution but expressing concern over valuation. The firm noted a one-year forward price-to-earnings ratio of 48x, suggesting the stock may be fully valued with potential downside of 19% from then-current levels.
Jefferies maintained a Hold recommendation on December 15, 2025, projecting a 15.16% upside with an average one-year price target of A$3.35. The firm noted that while Sigma’s projected annual revenue is expected to decrease by 38.34%, the projected annual non-GAAP EPS is anticipated to surge by 166.55% from prior forecasts, reflecting the margin-accretive nature of the Chemist Warehouse combination.
The divergence in analyst views centres on valuation versus growth potential. Bulls argue the merger creates a unique platform for capturing market share in a defensive, structurally growing sector supported by Australia’s aging demographics. Bears counter that the stock’s premium multiple leaves little room for execution missteps or competitive pressure.
Bull Case:
- Merger creates Australia’s largest pharmacy platform with unmatched scale advantages
- Defensive healthcare sector benefits from aging demographics and chronic disease growth
- A$100 million synergy target over four years supports margin expansion potential
Bear Case:
- Trading at 48x forward earnings leaves limited room for disappointment
- Projected 38% revenue decline suggests integration challenges or accounting adjustments ahead
- Macquarie’s A$2.50 target implies 19% downside risk from current levels
Goldman Sachs’ endorsement adds significant weight to the bullish case for Sigma Healthcare, yet with the stock trading at elevated multiples and one prominent bear warning of overvaluation, markets face a classic tension between growth optimism and valuation discipline, a dynamic that will likely be resolved only as the company demonstrates its ability to deliver on ambitious synergy targets and market share gains in coming quarters.
